// App-Quantinova.ai

5029 : Anti-Inflammatory, Immuno-Modulatory and Angiostatic Treatment As Third-Line Therapy for Multiple Myeloma (MM) a Combined Treatment Setting of Lenalidomide with Pioglitazone, Dexamethasone and Low-Dose Treosulfan (phase I/II)

Researchers

Presenter

  • Albrecht Reichle

Principal Investigators

  • Christina Hart

  • Matthias Grube

  • Reinhard Andreesen

Medical Centers

  • Department of Hematology/Oncology, University Hospital Regensburg, Regensburg, Germany

  • Hematology and Oncology, University Regensburg, Regensburg, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Venous thrombosis

Biomarkers

  • Immunoglobulin G

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Interferon alpha

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pioglitazone

  • Actoplus Met XR extended-release tablet

  • Lenalidomide

  • Thalidomide

  • Bortezomib

  • Ovastat

  • Interferon

  • Melphalan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved